Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rep. Pallone’s Energy And Commerce Win Is Salve For Generics

This article was originally published in The Pink Sheet Daily

Executive Summary

Anna Eshoo, who championed the brand-friendly biosimilars pathway, had challenged Pallone for ranking member post in House Energy and Commerce Committee.

You may also be interested in...



Waxman’s Congressional Exclusivity Set To Expire, But There Will Be No Equivalents

Retiring after 40 years in Congress, Waxman leaves an enormous legacy, but also many recent legislative defeats.

Follow-On Biologics: Defeat For Waxman, Win For Health Reform

Lopsided committee vote suggests that lengthy exclusivity is here to stay, which means that big pharma can get more comfortably behind the broader reform effort.

Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA

Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS076656

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel